Neuropharmacology of Huperzine A in Neurodegenerative Disorders

Huperzine A is a sesquiterpene alkaloid isolated from the club moss Huperzia serrata that exerts a spectrum of neuropharmacological effects relevant to neurodegenerative conditions. Its principal action is reversible inhibition of acetylcholinesterase, which elevates synaptic acetylcholine levels and enhances cholinergic transmission in regions affected by degenerative change. Beyond this symptomatic mechanism, emerging evidence indicates that Huperzine A modulates key pathways implicated in neuronal survival and degeneration. It influences the processing of amyloid precursor protein by downregulating β-secretase (BACE1) and presenilin-1 while upregulating α-secretase activity, resulting in reduced amyloid-β accumulation. Concomitantly, it attenuates tau hyperphosphorylation through inhibition of glycogen synthase kinase-3β and stabilises mitochondrial function, thereby mitigating oxidative stress and apoptotic signalling. Anti-inflammatory properties have been observed in microglial assays, with suppression of pro-inflammatory cytokines and cyclooxygenase-2 expression. Preclinical models also suggest modulation of neurotrophic factors and glutamatergic excitotoxicity via NMDA receptor antagonism. Clinically, randomised trials and meta-analyses have reported modest improvements in cognitive scores and activities of daily living in Alzheimer’s and vascular dementia, with a favourable tolerability profile. The convergence of cholinergic enhancement, disease-modifying potential and pleiotropic cellular protection positions Huperzine A as a promising candidate for further translational research and therapeutic development across a range of neurodegenerative disorders.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Neuropharmacology of Huperzine A in Neurodegenerative Disorders publication trend

The graph below shows the total number of articles in neuropharmacology of huperzine a in neurodegenerative disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Acetylcholinesterase (AChE): An enzyme that hydrolyses the neurotransmitter acetylcholine, terminating cholinergic signalling.

Amyloid precursor protein (APP): A membrane protein that, when cleaved by β-secretase and γ-secretase, yields neurotoxic amyloid-β peptides.

β-Secretase (BACE1): The enzyme responsible for the initial cleavage of APP that promotes amyloid-β formation.

Tau protein phosphorylation: A post-translational modification of the microtubule-associated protein tau, whose hyperphosphorylation contributes to neurofibrillary tangle formation.

Microglia: Resident immune cells of the central nervous system that mediate inflammatory responses.

References

1. Anti-neuroinflammatory effects of alkaloid-enriched extract from Huperzia serrata on lipopolysaccharide-stimulated BV-2 microglial cells. Pharmaceutical Biology (2023).
2. Huperzine A Regulates the Physiological Homeostasis of Amyloid Precursor Protein Proteolysis and Tau Protein Conformation—A Computational and Experimental Investigation. Biology (2024).
3. Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer’s Disease. Molecules (2021).
4. Huperzine A for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. PLOS ONE (2013).
5. Huperzine A in the Treatment of Alzheimer′s Disease and Vascular Dementia: A Meta‐Analysis. Evidence-based Complementary and Alternative Medicine (2014).